Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
BUSINESS
Mediator Sees Potential for Turnaround in Nichi-Iko’s Restructuring Plan
A third-party mediator for Nichi-Iko Pharmaceutical’s out-of-court debt workout process thinks the company’s draft restructuring plan is “reasonable” and “suggests the potential for a turnaround,” people familiar with the matter said. The organization made up of lawyers and certified accountants,…
To read the full story
Related Article
- Ex-Sandoz Japan Chief Tapped to Spearhead Nichi-Iko Turnaround
January 18, 2023
- Creditors Approve Nichi-Iko’s Turnaround Scheme, Grants Debt Waiver of 98.5 Billion Yen
January 5, 2023
- Nichi-Iko Asks for Debt Waiver from Creditors in Turnaround Plan
November 17, 2022
- Nichi-Iko to Be Delisted, Seeks Turnaround under Medipal-JWP Joint Firm; President to Bow Out
November 15, 2022
- Nichi-Iko Logs 35.6 Billion Yen in Excess Debt in April-September
November 15, 2022
- Nichi-Iko Slides into Excess Debt as Hefty Loss Booked by US Unit
November 9, 2022
- Creditors Defer Debts for Nichi-Iko until Turnaround Plan Is Approved
May 27, 2022
- Nichi-Iko Seeks Debt Workout amid US Pipeline Delays and Quality Woes, but President to Stay
May 16, 2022
- Nichi-Iko Files for Debt Reorganization, Incurs Loss of Over 100 Billion Yen
May 13, 2022
BUSINESS
- Boehringer Ingelheim in AMD Collab with Jichi Medical University
January 31, 2023
- BMS, Kyoto University Join Hands to Deliver Innovative Drugs
January 31, 2023
- Teijin Pharma’s Osteoporosis Med Ostabalo Now Available in Japan
January 31, 2023
- AnGes to Start Japan PII for NF-κB Decoy Oligo for Lower Back Pain
January 31, 2023
- Rexulti Filed for Major Depressive Disorder in Japan: Otsuka
January 31, 2023
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The advance of cell therapy is one of the most exciting innovations in medical treatment in recent years. These drugs offer potential curative treatments for severe or previously fatal diseases. In this article, I will explain features and challenges in…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…